215 related articles for article (PubMed ID: 36287444)
1. Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine.
Migotsky M; Beestrum M; Badawy SM
Pharmacy (Basel); 2022 Sep; 10(5):. PubMed ID: 36287444
[TBL] [Abstract][Full Text] [Related]
2. Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.
Dick MH; Abdelgadir A; Kulkarni VV; Akram H; Chatterjee A; Pokhrel S; Khan S
Cureus; 2022 May; 14(5):e24920. PubMed ID: 35706735
[TBL] [Abstract][Full Text] [Related]
3. Sickle Cell Disease: A Review.
Kavanagh PL; Fasipe TA; Wun T
JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of l-glutamine versus crizanlizumab for adults with sickle cell disease: model focused on reducing pain episode costs from Qatar's healthcare perspective.
Adel AM; Abushanab D; Al-Badriyeh D; Hamad A; Alshurafa A; Yassin MA
SAGE Open Med; 2024; 12():20503121231224551. PubMed ID: 38711465
[TBL] [Abstract][Full Text] [Related]
5. Contemporary Management and Prevention of Vaso-Occlusive Crises (VOCs) in Adults With Sickle Cell Disease.
Weaver SB; Rungkitwattanakul D; Singh D
J Pharm Pract; 2023 Feb; 36(1):139-148. PubMed ID: 34151636
[TBL] [Abstract][Full Text] [Related]
6. Use of Disease-Modifying Treatments in Patients With Sickle Cell Disease.
Newman TV; Yang J; Suh K; Jonassaint CR; Kane-Gill SL; Novelli EM
JAMA Netw Open; 2023 Nov; 6(11):e2344546. PubMed ID: 37991760
[TBL] [Abstract][Full Text] [Related]
7. Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.
Han J; Saraf SL; Gordeuk VR
Pharmacotherapy; 2020 Jun; 40(6):535-543. PubMed ID: 32350885
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials.
Ali MA; Ahmad A; Chaudry H; Aiman W; Aamir S; Anwar MY; Khan A
Exp Hematol; 2020 Dec; 92():11-18.e1. PubMed ID: 32841705
[TBL] [Abstract][Full Text] [Related]
9. Advancements in Sickle Cell Disease (SCD) Treatment: A Review of Novel Pharmacotherapies and Their Impact on Patient Outcomes.
Khan SJ; Zaidi SAT; Murtaza SF; Asif M; Kumar V
Cureus; 2023 Aug; 15(8):e42847. PubMed ID: 37664319
[TBL] [Abstract][Full Text] [Related]
10. An update review of new therapies in sickle cell disease: the prospects for drug combinations.
Lugthart S; Ginete C; Kuona P; Brito M; Inusa BPD
Expert Opin Pharmacother; 2024 Feb; 25(2):157-170. PubMed ID: 38344818
[TBL] [Abstract][Full Text] [Related]
11. Short- and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: A case report.
Alshurafa A; Yassin MA
Front Med (Lausanne); 2022; 9():1048571. PubMed ID: 36523780
[TBL] [Abstract][Full Text] [Related]
12. Recurrence of acute chest syndrome post stopping Crizanlizumab, the dilemma of stopping vs continuation in patient with sickle cell disease: case report.
Afana MS; Abu-Tineh M; Alshurafa A; Yasin AK; Ahmed K; Abdulgayoom M; Yassin MA
Hematology; 2023 Dec; 28(1):2229115. PubMed ID: 37519115
[TBL] [Abstract][Full Text] [Related]
13. Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease.
Stevens DL; Hix M; Gildon BL
J Pharm Technol; 2021 Aug; 37(4):209-215. PubMed ID: 34752581
[No Abstract] [Full Text] [Related]
14. Therapeutic perspective for children and young adults living with thalassemia and sickle cell disease.
Ferraresi M; Panzieri DL; Leoni S; Cappellini MD; Kattamis A; Motta I
Eur J Pediatr; 2023 Jun; 182(6):2509-2519. PubMed ID: 36997768
[TBL] [Abstract][Full Text] [Related]
15. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Ataga KI; Kutlar A; Kanter J; Liles D; Cancado R; Friedrisch J; Guthrie TH; Knight-Madden J; Alvarez OA; Gordeuk VR; Gualandro S; Colella MP; Smith WR; Rollins SA; Stocker JW; Rother RP
N Engl J Med; 2017 Feb; 376(5):429-439. PubMed ID: 27959701
[TBL] [Abstract][Full Text] [Related]
16. Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease.
Osunkwo I; Manwani D; Kanter J
Ther Adv Hematol; 2020; 11():2040620720955000. PubMed ID: 33062233
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacovigilance assessment of adverse events associated with the use of hydroxyurea, L-glutamine, voxelotor, and crizanlizumab in sickle cell disease.
Chen M; Hankins JS; Zhang M; Ataga KI
Am J Hematol; 2024 Feb; 99(2):E37-E41. PubMed ID: 37950855
[TBL] [Abstract][Full Text] [Related]
18. An expert review of voxelotor for the treatment of hemolytic anemia in patients with sickle cell disease: 'bridging the gap between laboratory data and patient related outcomes'.
Inusa BPD; Mnika K; Babiker S
Expert Rev Hematol; 2023; 16(8):585-591. PubMed ID: 37329253
[TBL] [Abstract][Full Text] [Related]
19. Crizanlizumab in sickle cell disease.
Kaur K; Kennedy K; Liles D
Pain Manag; 2023 Oct; ():. PubMed ID: 37850353
[TBL] [Abstract][Full Text] [Related]
20. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
Howard J; Ataga KI; Brown RC; Achebe M; Nduba V; El-Beshlawy A; Hassab H; Agodoa I; Tonda M; Gray S; Lehrer-Graiwer J; Vichinsky E
Lancet Haematol; 2021 May; 8(5):e323-e333. PubMed ID: 33838113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
